Original Source(s)
Related Content
The role of protein lactylation in skin diseases: from molecular mechanisms to potential therapeutics
July 1, 2026
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min